Analysts Set Cardlytics, Inc. (NASDAQ:CDLX) Target Price at $6.92

Cardlytics, Inc. (NASDAQ:CDLXGet Free Report) has earned an average recommendation of “Hold” from the seven analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $6.92.

Several analysts have issued reports on the company. Craig Hallum upgraded Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Northland Capmk lowered Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th. Evercore ISI began coverage on Cardlytics in a research note on Friday, October 11th. They set an “in-line” rating and a $4.00 price objective on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Cardlytics in a research note on Thursday, November 7th. Finally, Northland Securities downgraded shares of Cardlytics from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $7.00 to $5.00 in a research report on Friday, August 16th.

View Our Latest Analysis on Cardlytics

Insider Buying and Selling at Cardlytics

In other Cardlytics news, CFO Alexis Desieno sold 25,118 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $3.43, for a total value of $86,154.74. Following the sale, the chief financial officer now owns 116,481 shares in the company, valued at approximately $399,529.83. This trade represents a 17.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Amit Gupta sold 22,607 shares of Cardlytics stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the sale, the chief executive officer now directly owns 178,519 shares in the company, valued at approximately $687,298.15. This trade represents a 11.24 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 68,691 shares of company stock worth $237,767. 4.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. RBF Capital LLC raised its stake in shares of Cardlytics by 311.9% during the third quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock valued at $1,562,000 after purchasing an additional 369,620 shares in the last quarter. GSA Capital Partners LLP raised its position in shares of Cardlytics by 1,273.2% during the 3rd quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock worth $1,223,000 after buying an additional 354,474 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Cardlytics by 711.9% in the 2nd quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock worth $2,882,000 after acquiring an additional 307,800 shares during the period. Kent Lake Capital LLC acquired a new stake in shares of Cardlytics in the 1st quarter worth approximately $3,622,000. Finally, Perbak Capital Partners LLP bought a new position in shares of Cardlytics in the first quarter valued at approximately $2,348,000. Institutional investors own 68.10% of the company’s stock.

Cardlytics Stock Performance

Cardlytics stock opened at $3.44 on Friday. Cardlytics has a 52 week low of $2.89 and a 52 week high of $20.52. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. The stock has a market cap of $174.83 million, a P/E ratio of -0.56 and a beta of 1.61. The stock has a 50 day moving average of $3.73 and a 200-day moving average of $6.25.

Cardlytics (NASDAQ:CDLXGet Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.18. The company had revenue of $67.06 million during the quarter, compared to analyst estimates of $57.77 million. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. The firm’s revenue for the quarter was down 15.1% compared to the same quarter last year. During the same period last year, the business earned ($0.26) EPS. On average, analysts expect that Cardlytics will post -1.52 EPS for the current fiscal year.

About Cardlytics

(Get Free Report

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

Featured Articles

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.